Gilead Sciences stock predicted to gain 35% after retesting breakout level

9 articles · Updated · Barron's · Apr 28

Gilead Sciences is trading around $128 and is retesting an 11-year cup base breakout pivot at $123.47, with technical analysis forecasting a move to $173 by year-end.
Despite an 8% decline this month and falling eight of the last ten weeks, Gilead has gained 22% over the past year and remains above key moving averages, suggesting a potential buying opportunity.
The stock’s resilience contrasts with broader healthcare sector weakness, as biotech ETFs show mixed performance; holding support could reinforce bullish sentiment for both Gilead and the biotech sector overall.

Can Gilead's $13B acquisition spree deliver 10+ blockbuster drugs by 2030?

Is Gilead's stock pullback a golden buying opportunity or a bull trap?

What is the single biggest risk to Gilead's promising drug pipeline in 2026?

How will new price controls affect the future of costly CAR-T cancer therapies?

Will Gilead's pivot to oncology successfully replace its long-term reliance on HIV?

Is AI the key to solving big pharma's drug affordability crisis?